Presentations
November 2024
Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, Effectively Depletes Low-Expressing CD20+ B cells in Preclinical Models of Autoimmune Disease
ACR Convergence 2024 — November 14-19, 2024
June 2024
Therapeutic Potential of Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, for the Treatment of Refractory Autoimmune Disease Patients
EULAR 2024 Congress — June 12-15, 2024
March 2024
AACR 2024 Presentations
AACR ANNUAL MEETING 2024 April 5-10, 2024 San Diego Convention Center, San Diego, CA April 7, 2024, 3:40 PM – 3:55 PM | Session MS.IM01.03 ...